SYGNIS Announces Outcome Of Annual General Meeting 2017

Published: Jul 10, 2017

• Shareholders approve all Management Board proposals

Madrid, Spain and Heidelberg, Germany, July 7, 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announces that the Annual General Meeting (AGM) held in Heidelberg today, July 7, 2017, approved all Management Board proposals. Participating shareholders, representing 31.66 percent of the total share capital of nearly 44.9 million shares, approved all proposals by a large majority.

At the meeting, CEO Dr. Heikki Lanckriet discussed the rationale behind the recent acquisition of Innova Biosciences Ltd. and related financial details. “The acquisition of Innova Biosciences marks an important step towards SYGNIS’ ability to offer a complete molecular biology portfolio. The new technologies and products will accelerate our corporate growth,” Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said. “On behalf of all of us at SYGNIS, I would like to thank our shareholders for placing their confidence in us. Today’s vote reinforces their support for our ‘grow, buy and build’ strategy, including the Innova acquisition, which we believe has put us on a solid path towards profitability and long-term, sustainable success.”

The AGM approved the discharge of the members of the Supervisory Board and the Management Board for fiscal year 2016, and the appointment of Ernst & Young, Mannheim as auditors for fiscal year 2017.

The AGM also approved the implementation of Stock Option Plan 2017 and the creation of a new conditional capital (Conditional Capital 2017) for the fulfillment of the stock option plan as well as the related amendment to the Articles of Association.

As the terms of all members ended today, the AGM elected a new Supervisory Board. The following members were re-elected to serve another four-year term: Dr. Cristina Garmendia Mendizábal (Chairwoman), Joseph M. Fernández (Vice Chairman), Dr. Trevor Jarman and Tim McCarthy. Maria Jesús Sabatés Mas and Dr. Franz Wilhelm Hopp did not stand for re-election. They were replaced by Peter Llewellyn-Davies and Pilar de la Huerta. Pilar de la Huerta resigned from the SYGNIS Management Board effective today. Dr. Garmendia Mendizábal thanked Ms Sabatés Mas and Dr. Hopp for their collaboration during the last years and welcomed the new members to the Supervisory Board.

Furthermore, the AGM resolved to cancel the remaining existing authorized capitals and create a new authorized capital in the amount of EUR 22,467,043.00 (Authorized Capital 2017). The meeting authorized the Management Board to exclude shareholder subscription rights with the consent of the Supervisory Board and approved the corresponding amendment to the Articles of Association.

The AGM also approved an amendment to the Articles of Association regarding Supervisory Board resignations, creating a notice period of three (3) weeks if the resignation is not for good cause.

The AGM voting results for each agenda item will be published in the near future in the Investors section of SYGNIS’ website.

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone : +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG
Raimund Gabriel
Managing Partner
Email: sygnis@mc-services.eu

About SYGNIS AG: http://www.sygnis.com

SYGNIS AG specializes in the development and commercialization of proprietary technologies and offers a wide range of commercial products addressing key challenges in molecular biology. With the 2016 acquisition of Expedeon Holdings, Ltd. based in the UK, SYGNIS added a complementary proteomics product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. In addition, SYGNIS acquired the profitable U.S.-based life sciences tools company C.B.S. Scientific in December 2016 to further expand its product offering. In June 2017, the Company acquired Innova Biosciences Ltd., world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The products of SYGNIS Group are sold through a direct sales force and several distribution partners in Europe, the U.S. and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the U.S. as well as sales offices in Asia. The company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

Back to news